Notice: Internet Explorer 11 users may encounter issues loading pages throughout the website. Please turn on IE-11’s compatibility mode while we work to resolve the issue.

>

MEETINGS / EVENTS

RSS

May 05 - 07 2014, 12:00 AM - 12:00 AM

2014 ASA Legislative Conference

>

FDA MEDWATCH ALERTS

April 21, 2014

Lidocaine HCI Injection, USP, by Hospira: Recall - Visible Particulates

Summary:

Lidocaine HCI Injection USP by Hospira Recall Visible Particulates

April 18, 2014

Propofol Injectable Emulsion, USP by Hospira: Recall - Visible Particulates

Summary:

Propofol Injectable Emulsion USP by Hospira Recall Visible Particulates

April 18, 2014

FDA MedWatch - ARKON Anesthesia Delivery System with Version 2.0 Software by Spacelabs Healthcare: Class I Recall

Summary:

FDA MedWatch Class I Recall 4 18 14

>

ASA FEATURED PRODUCT

Add this product to your shopping cart

Anesthesiology Continuing Education (ACE) Program

SKU: 30702-14CE

... Read more »

Single Copies, Member Price: $360

ASA Letter to FDA on Thiopental Shortage

Monday, January 10, 2011

 ASA submitted a letter to the Food and Drug Administration (FDA) regarding the shortage of the drug Thiopental.

In the letter, ASA explains the cause of the shortage:

"Within the last two years, however, the United States experienced significant shortages of propofol as a result of simultaneous manufacturing problems and one of the three propofol manufacturers exiting the market. This led to a sharp increase in the demand for other induction agents, including thiopental. During this time, however, the U.S. saw its thiopental supplies reduced, and domestic production discontinued. These coinciding events have led to a dangerous reduction in the availability of anesthesia induction medications to the point that the safety of American patients is now in jeopardy."  

ASA has a webpage dedicated to Drug Shortages that can be viewed here.

Click here to view the letter to the FDA.

 

 

« Back to Washington Alerts